Breakthrough: ExpreS2ion launches first unique cell line for enhanced efficacy of vaccines and immunotherapy
After several years of research and development, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces the launch of a new tailormade S2 cell line, HighMan-S2™. This is the first member of ExpreS2ion’s new functionally modified S2 product line, GlycoX-S2™, which utilises and expands the advantages of the ExpreS2 platform.
For several years, ExpreS2ion has been working on the development of adding functional modifications to its powerful ExpreS2 platform. This makes the introduction of the new HighMan-S2™ cell line an important milestone for the Company. The cell line is engineered for scalable production of proteins with enhanced immunological properties for novel vaccines and immunotherapy. It is thus a demonstration of a successful combination of the advantages of the Company´s ExpreS2 platform and specifically enhanced immunogenicity.
“I am very proud that we are now able to present the first functionally engineered product to the market. It is the result of a long-term endeavour to develop modified additions to our well established ExpreS2 platform, addressing the specific needs in the immunotherapy and vaccine market”, says ExpreS2ion’s CEO Dr. Steen Klysner.
The new product: Enhancing immunity
The first product is a high mannose ExpreS2 cell line. Sugar groups on the surface, so-called glycosylation, is an important feature of natural proteins. By altering the traditional S2 glycosylation to a structure containing a high number of the sugar mannose, the immune reaction towards the protein is enhanced. This has the potential to significantly enhance the efficacy of vaccines, which are made using the HighMan-S2™ cell line.
Interest from potential partners and clients
Apart from being implemented in ExpreS2ion’s own projects, potential partners and clients have shown interest in the new HighMan-S2™ cell line as well.
The new cell line is the first product of several glyco-modified products to come to the market under the name GlycoX-S2™ products. Combining the unique characteristics of the ExpreS2 system with specific features for selected product segments is unique and expected to increase the product demand significantly.
The ExpreS2 platform is well documented to be exceptional in its ability to enable production of complex and difficult to produce proteins. This is now enforced by adding functional features matching specific market needs, a development that was strongly accelerated by the access to the CRISPR/CAS9 technology, which the Company licenced earlier this year. ExpreS2ion expects that the new HighMan-S2™ cell line together with other products under development in the GlycoX-S2™ portfolio will create a strong competitive edge for the Company and future products based on the ExpreS2 system.
The new system will be launched at World Vaccine Congress Europe in Barcelona on 30th October 2019, which includes a presentation by the Company’s CSO Dr. Wian de Jongh.
Svensk Kapitalmarknadsgranskning AB
Telephone: +46 70 755 95 51
For further information about ExpreS2ion Biotech Holding AB, please contact:
Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on 24 October, 2019.
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS, which was founded in 2017. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.